(NASDAQ: CDMO) Avid Bioservices's forecast annual revenue growth rate of 17.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Avid Bioservices's revenue in 2023 is $140,938,000.On average, 2 Wall Street analysts forecast CDMO's revenue for 2024 to be $9,783,110,119, with the lowest CDMO revenue forecast at $9,656,631,643, and the highest CDMO revenue forecast at $9,909,588,595. On average, 2 Wall Street analysts forecast CDMO's revenue for 2025 to be $11,749,850,420, with the lowest CDMO revenue forecast at $10,851,853,241, and the highest CDMO revenue forecast at $12,647,847,600.
In 2026, CDMO is forecast to generate $14,500,757,273 in revenue, with the lowest revenue forecast at $12,875,508,857 and the highest revenue forecast at $16,126,005,690.